'Cancer Institute' posts
To those of us who work in the field, this data comes as no surprise; the trend of bilateral mastectomies is a known phenomenon. More than 10 years ago, I remember the chatter among surgeons at national meetings asking if others noticed that more and more, younger women were coming in asking for bilateral mastectomies. Back in 2007, Dr. Todd Tuttle authored a study in the Journal of Clinical Oncology that found that the rate of contralateral prophylactic mastectomy was on the rise, from just under 2% in 1998 to 5% in 2003. This week’s study only validates that this upward trend shows no sign of leveling off.
Why do patients choose bilateral mastectomies?
Many women ....
International hematology expert Dr. John Pagel recruited to expand Swedish’s treatment for, and research on, blood cancers
SEATTLE — September 8, 2014 — The Swedish Cancer Institute is launching a Hematologic Malignancies program for the expanded treatment and research of blood-based cancers such as leukemia, multiple myeloma and lymphoma. Newly recruited international hematology expert John Pagel, M.D., Ph.D., will serve as chief of the new program, which launches this month.
“Dr. Pagel brings with him a world-class reputation for research and excellence in patient care,” said Swedish Cancer Institute Executive Director Thomas Brown, M.D. “This new program will add to our existing strengths in caring for patients with hematologic malignancies and further develop our autologous hematopoietic stem cell program. These efforts allow the Swedish Cancer Institute to continue providing the most versatile and comprehensive cancer care in the Pacific Northwest.”
Dr. Pagel’s practice will include caring for patients with acute and chronic leukemias, multiple myeloma, Hodgkin and non-Hodgkin lymphomas, and myelodysplastic syndromes, as well as other myeloproliferative disorders. In addition to providing established treatments such as autologous stem cell transplants, the program will develop novel therapies for the treatment of blood-based diseases through research collaborations and studies initiated by Swedish Cancer Institute physicians.
The Red Door campaign was established to ...
Can you believe the month of August has already arrived? Some may see the end of August as an end to summer, but it doesn’t mean the end of community events. Two particular events taking place toward the end of August are the American Cancer Society Relay for Life—Capitol Hill event and the Northwest Hope and Healing Alki Beach Run 5K. We are happy to announce the Swedish Cancer Institute will be supporting both!
On Saturday, August 23rd ...
Ultrasound technology has undergone a dramatic improvement in recent years providing clear and precise images without exposing the patient to any radiation. Thyroid nodules that are suspicious for malignancy can now be identified before they are large enough to be felt in the neck by the patient or health care provider.
When a ...
PALB2 is a gene that was first linked to hereditary breast cancer risk back in 2007. Today’s Seattle Times reports on a recent study about PALB2 that was just published in the New England Journal of Medicine. The study, the largest to date, detailed the breast cancer risks faced by women – and to a lesser extent, men – who carry a mutation in their PALB2 gene. The breast cancer risks were several times greater than the ~12% risk faced by all women, and varied with the woman’s age and family history. Currently, there is no consistent evidence to suggest that men or women who carry a single PALB2 gene mutation are at greater risks of developing ovarian or other cancers.
PALB2 genetic testing can provide very important information that can help women and their families better understand and reduce their risks of developing breast cancer. However, even among women with a very strong personal or family history of breast cancer, very few will test positive. Studies suggest that only about 1-3% of high risk women will carry a PALB2 mutation. In my personal experience, I have tested about 300 high risk women for PALB2 mutations, and ...
How to tell if a skin lesion is concerning
Warning signs include moles larger than a pencil eraser head, change in size, change in color, itching, bleeding or scab forming over the mole. Areas of particular concern include face, neck, back and extremities. However, skin cancers can also develop in areas where the sun does not shine.
What to do if I have a skin cancer?
If you have a mole or skin lesion that is concerning, bring it up with your family physician who may biopsy it or refer you ..